Drugs / Vinblastine
last change Sep 2026 re-read 8 days ago

Vinblastine

Small molecule

Developed for
lymphoma · Hodgkins lymphoma · classic Hodgkin lymphoma · urinary bladder cancer · renal pelvis/ureter urothelial carcinoma · lung cancer · infiltrating bladder urothelial carcinoma · low grade glioma
+63 more · melanoma · prostate cancer · urethra cancer · bladder transitional cell carcinoma · central nervous system neoplasm · cutaneous melanoma · extragonadal germ cell tumor · Hodgkin's lymphoma, lymphocytic depletion · Hodgkin's lymphoma, mixed cellularity · nodular sclerosis classical Hodgkin lymphoma · urinary bladder carcinoma · urothelial carcinoma · cancer · glioma · metastatic melanoma · neurofibromatosis type 1 · non-Hodgkin lymphoma · skin cancer · testicular germ cell tumor · ureter cancer · acute lymphoblastic leukemia · acute myeloid leukemia · adult nodular lymphocyte predominant Hodgkin lymphoma · ALK-positive anaplastic large cell lymphoma · anterior urethra cancer · bladder mixed adenocarcinoma · bladder squamous cell carcinoma · breast cancer · central nervous system disorder · cervical cancer · childhood germ cell tumor · childhood low-grade glioma · childhood malignant neoplasm · desmoid tumor · diffuse large B-cell lymphoma · Ewing sarcoma · grade II glioma · Hodgkin's lymphoma, lymphocytic-histiocytic predominance · infiltrating bladder urothelial carcinoma sarcomatoid variant · infiltrating bladder urothelial carcinoma, clear cell variant · Kaposi's sarcoma · kidney cancer · kidney neoplasm · Langerhans cell histiocytosis specific to childhood · low-grade astrocytoma · lymphoblastic lymphoma · malignant mesothelioma · metastatic malignant neoplasm · micropapillary variant infiltrating bladder urothelial carcinoma · nested variant infiltrating bladder urothelial carcinoma · non-small cell lung carcinoma · ovarian carcinoma · peripheral T-cell lymphoma, not otherwise specified · plasmacytoid variant infiltrating bladder urothelial carcinoma · posterior urethra cancer · primary pulmonary vein stenosis · sarcoma · transitional cell carcinoma · B-cell childhood acute lymphoblastic leukemia · high grade B-cell lymphoma · Langerhans cell histiocytosis · mixed neuronal-glial tumor · pleomorphic xanthoastrocytoma
Investigated by
National Cancer Institute (NCI) · European Organisation for Research and Treatment of Cancer - EORTC · M.D. Anderson Cancer Center · Eastern Cooperative Oncology Group · SWOG Cancer Research Network · Seagen Inc.
+129 more · St. Jude Children's Research Hospital · Cancer and Leukemia Group B · Children's Oncology Group · Fondazione Italiana Linfomi - ETS · Memorial Sloan Kettering Cancer Center · Stanford University · The Hospital for Sick Children · Alliance for Clinical Trials in Oncology · Children's Cancer and Leukaemia Group · Gustave Roussy, Cancer Campus, Grand Paris · Medical Research Council · Merck Sharp & Dohme LLC · University of Cologne · Children's Hospital of Philadelphia · Northwestern University · UNICANCER · University of Washington · Amgen · AstraZeneca · Brigham and Women's Hospital · Bristol-Myers Squibb · Canadian Cancer Trials Group · Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte · Children's Cancer Group · Christine Mauz-Körholz · City of Hope Medical Center · Dana-Farber Cancer Institute · ECOG-ACRIN Cancer Research Group · Fox Chase Cancer Center · Genentech, Inc. · Lymphoma Study Association · NCIC Clinical Trials Group · NRG Oncology · Radiation Therapy Oncology Group · University of Southern California · Academic and Community Cancer Research United · Anticancer Fund, Belgium · Arbeitsgemeinschaft Urologische Onkologie · Asan Medical Center · Assistance Publique Hopitaux De Marseille · Australasian Leukaemia and Lymphoma Group · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · Barbara Ensoli, MD, PhD · Bayer · Beth Israel Deaconess Medical Center · Boston Children's Hospital · Brain Tumour Program · British Thoracic Society · CTD-CNO · California Pacific Medical Center Research Institute · Cancer Research UK · Case Comprehensive Cancer Center · Centre Hospitalier Universitaire Dijon · Centre Oscar Lambret · Centre for Human Drug Research, Netherlands · Centro di Riferimento Oncologico - Aviano · Children's Hospital of Orange County · Consorzio Mario Negri Sud · Daniel Morgenstern · Dartmouth-Hitchcock Medical Center · Deutsche AIDS Gesellschaft e.V. · Deutsche Krebshilfe e.V., Bonn (Germany) · Duke University · ECS-Progastrin SA · Eli Lilly and Company · Euronet Worldwide · European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma · French Innovative Leukemia Organisation · GITIL (GRUPPO ITALIANO TERAPIE INNOVATIVE NEI LINFOMI) · German Hodgkin's Lymphoma Study Group · Groupe D'Etude des Tumeurs Uro-Genitales · Harlachinger Krebshilfe e.V. · Helen DeVos Children's Hospital · Hellenic Oncology Research Group · all 135 on the full record

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved US (FDA) VELBAN — 1965-11-25 fda.gov ↗

Trials 152 · started per year

today
US approved 1965
2
1
1
2
5
3
10
7
6
6
7
4
3
6
2
3
6
6
4
7
3
2
6
1
2
4
7
4
6
3
5
2
1
6
4
3
19651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 02 trials
Phase 0 NCT06204614 Jun 2024 → Jul 2028 expected infiltrating bladder urothelial carcinoma Brigham and Women's Hospital Enrolling by invitation No outcome recorded
Phase 0 NCT06381570 Mar 2024 → Mar 2027 expected low grade glioma Daniel Morgenstern Recruiting No outcome recorded
Phase 15 trials
Phase 1 NCT02343718 Jun 2015 → Sep 2017 cancer, central nervous system disorder, lymphoma Canadian Cancer Trials Group Completed No outcome recorded
Phase 1 NCT01884922 May 2013 → Sep 2015 low grade glioma Gustave Roussy, Cancer Campus, Grand Paris Completed No outcome recorded
Phase 1 NCT01135563 Apr 2010 → Apr 2012 cancer, central nervous system neoplasm The Hospital for Sick Children Completed No outcome recorded
Phase 1 NCT00352495 Jun 2006 → Sep 2011 central nervous system neoplasm, neurofibromatosis type 1 Children's Oncology Group Completed No outcome recorded
Phase 1 NCT00001570 Feb 1997 → Jan 2001 kidney neoplasm, metastatic malignant neoplasm National Cancer Institute (NCI) Completed No outcome recorded
Phase 1/27 trials · 1 met primary
Phase 1/2 NCT06666348 Jan 2026 → Apr 2030 expected childhood low-grade glioma St. Justine's Hospital Recruiting No outcome recorded
Phase 1/2 NCT03585465 Mar 2019 → May 2025 childhood malignant neoplasm Centre Oscar Lambret Terminated No outcome recorded
Phase 1/2 NCT03331341 Jan 2019 → Dec 2023 classic Hodgkin lymphoma University of Washington Completed Met primary
Phase 1/2 NCT01771107 Mar 2013 → Oct 2021 HIV infectious disease, classic Hodgkin lymphoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 1/2 NCT01743157 Dec 2010 → May 2013 metastatic melanoma California Pacific Medical Center Research Institute Completed No outcome recorded
Phase 1/2 NCT01196416 Aug 2010 → Aug 2015 cutaneous melanoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 1/2 NCT00147875 Mar 2004 → Jul 2007 Hodgkins lymphoma University of Cologne Completed No outcome recorded
Phase 280 trials · 3 met primary · 1 missed
Phase 2 NCT06290687 Sep → Dec 2026 infiltrating bladder urothelial carcinoma Case Comprehensive Cancer Center Withdrawn No outcome recorded
Phase 2 NCT07551583 Aug 2026 → Dec 2030 expected Hodgkins lymphoma M.D. Anderson Cancer Center Recruiting No outcome recorded
Phase 2 NCT07013565 Aug 2025 → Jul 2029 expected ALK-positive anaplastic large cell lymphoma New York Medical College Recruiting No outcome recorded
Phase 2 NCT06960577 May 2025 → Aug 2028 expected urinary bladder cancer AstraZeneca Recruiting No outcome recorded
Phase 2 NCT06984146 Apr 2025 → Jan 2028 expected classic Hodgkin lymphoma National Medical Research Radiological Centre of the Ministry of Health of Russia Recruiting No outcome recorded
Phase 2 NCT06745076 Mar 2025 → Jan 2032 expected classic Hodgkin lymphoma University of Washington Recruiting No outcome recorded
Phase 2 NCT07234487 Oct 2024 → Oct 2029 expected classic Hodgkin lymphoma St. Petersburg State Pavlov Medical University Recruiting No outcome recorded
Phase 2 NCT06486337 Jul 2024 → Aug 2027 expected non-Hodgkin lymphoma The First Affiliated Hospital of Soochow University Recruiting No outcome recorded
Phase 2 NCT06377566 Apr 2024 → Apr 2027 expected Hodgkins lymphoma Memorial Sloan Kettering Cancer Center Recruiting No outcome recorded
Phase 2 NCT06164275 Feb 2024 → Jul 2025 overdue classic Hodgkin lymphoma Northwestern University Active not recruiting No outcome recorded
Phase 2/33 trials · 1 missed
Phase 2/3 NCT04628767 Nov 2021 → Sep 2027 expected renal pelvis/ureter urothelial carcinoma National Cancer Institute (NCI) Recruiting No outcome recorded
Phase 2/3 NCT00784537 Sep 2008 → Jan 2015 Hodgkins lymphoma Fondazione Italiana Linfomi - ETS Completed Missed primary
Phase 2/3 NCT00014274 Jan 2001 → Mar 2008 renal pelvis/ureter urothelial carcinoma, urethra cancer, urinary bladder cancer European Organisation for Research and Treatment of Cancer - EORTC Completed No outcome recorded
Phase 343 trials · 4 met primary · 9 missed
Phase 3 NCT05675410 May 2023 → Apr 2031 expected Hodgkins lymphoma National Cancer Institute (NCI) Recruiting No outcome recorded
Phase 3 NCT04685616 Apr 2022 → Sep 2030 expected Hodgkins lymphoma University College, London Recruiting No outcome recorded
Phase 3 NCT04576117 Feb 2021 → Dec 2026 expected grade II glioma, low-grade astrocytoma National Cancer Institute (NCI) Active not recruiting No outcome recorded
Phase 3 NCT04638790 Feb 2020 → Dec 2026 expected classic Hodgkin lymphoma State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia Recruiting No outcome recorded
Phase 3 NCT03159897 Aug 2017 → Nov 2021 classic Hodgkin lymphoma Fondazione Italiana Linfomi - ETS Completed No outcome recorded
Phase 3 NCT03296306 Sep 2016 → Aug 2021 transitional cell carcinoma, ureter cancer, urethra cancer, urinary bladder cancer Asan Medical Center Unknown No outcome recorded
Phase 3 NCT01652261 May 2013 → Oct 2014 Hodgkins lymphoma European Organisation for Research and Treatment of Cancer - EORTC Withdrawn No outcome recorded Stop: Enrollment
Phase 3 NCT01358747 May 2011 → ? Hodgkins lymphoma Centre Hospitalier Universitaire Dijon Completed Met primary
Phase 3 NCT00433433 Oct 2006 → Dec 2011 lymphoma European Organisation for Research and Treatment of Cancer - EORTC Unknown Missed primary
Phase 3 NCT00274950 May 2005 → May 2010 childhood germ cell tumor, extragonadal germ cell tumor, ovarian carcinoma Children's Cancer and Leukaemia Group Unknown No outcome recorded
Phase 43 trials
Phase 4 NCT03500133 Oct 2017 → Oct 2027 expected Hodgkins lymphoma Hospital JP Garrahan Recruiting No outcome recorded
Phase 4 NCT03092986 Jan 2017 → Jun 2018 non-small cell lung carcinoma Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh Completed No outcome recorded
Phase 4 NCT01088750 Nov 2009 → Oct 2023 lymphoma Christine Mauz-Körholz Completed No outcome recorded
Phase not applicable9 trials
— NCT01868451 May 2013 → Jun 2026 Hodgkins lymphoma Memorial Sloan Kettering Cancer Center Completed No outcome recorded
— NCT01578967 Apr 2012 → Aug 2016 Hodgkins lymphoma UNC Lineberger Comprehensive Cancer Center Completed No outcome recorded
— NCT00901303 Oct 2008 → Jun 2010 Hodgkins lymphoma Weill Medical College of Cornell University Terminated No outcome recorded Stop: Enrollment
— NCT00317408 Apr 2004 → Feb 2014 lymphoma European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma Unknown No outcome recorded
— NCT00187057 Sep 2002 → Aug 2006 ataxia telangiectasia St. Jude Children's Research Hospital Completed No outcome recorded
— NCT00276757 Apr 2001 → Jun 2013 Langerhans cell histiocytosis specific to childhood Histiocyte Society Completed No outcome recorded
— NCT00187070 Dec 1997 → Jul 2001 non-Hodgkin lymphoma St. Jude Children's Research Hospital Completed No outcome recorded
— NCT00416377 — lymphoma Children's Cancer and Leukaemia Group Unknown No outcome recorded
— NCT00417014 — lymphoma Children's Cancer and Leukaemia Group Unknown No outcome recorded
Comparator or background therapy56 trials
Phase 1 NCT01056679 Background Apr 2010 → Apr 2014 Hodgkins lymphoma University of Cologne Completed No outcome recorded
Phase 1 NCT01060904 Background Jan 2010 → Sep 2012 Hodgkins lymphoma Seagen Inc. Completed No outcome recorded
Phase 1 NCT00498979 Background May 2007 → May 2010 melanoma Case Comprehensive Cancer Center Completed No outcome recorded
Phase 1 NCT00006212 Background Nov 1999 → ? lung cancer Center for Molecular Medicine Unknown No outcome recorded
Phase 1 NCT00002887 Background Jul 1995 → ? lung cancer Ottawa Regional Cancer Centre Unknown No outcome recorded

News releases announcing trial results or a regulatory action · 8

DateIssuerRelease
2026-06-01 Bristol-Myers Squibb Regulatory Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma bms.com ↗
This approval marks a significant milestone, establishing the Opdivo plus AVD combination as the first immunotherapy-based regimen available in the European Union (EU) for newly diagnosed advanced cHL.
2026-03-20 Bristol-Myers Squibb Regulatory Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab) bms.com ↗
The U.S. Food and Drug Administration (FDA) granted approval of Opdivo in combination with doxorubicin, vinblastine and dacarbazine (AVD) for the treatment of adult and pediatric patients 12 years and older with previously untreated, Stage III or IV cHL.
2025-12-11 Bristol-Myers Squibb Regulatory U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma bms.com ↗
2023-09-07 Intensity Therapeutics, Inc. Regulatory Intensity Therapeutics Receives Orphan Drug Designation for the three key ingredients in INT230-6 for the Treatment of Soft Tissue Sarcoma intensitytherapeutics.com ↗
the US Food and Drug Administration's Office of Orphan Products Development has granted orphan-drug designation for the treatment of soft tissue sarcoma (STS) to the three active moieties comprising INT230-6, cisplatin, vinblastine sulfate, and the diffusion enhancer SHAO-FA (8-((2-hydroxybenzoyl) amino)octanoate).
2022-11-10 Intensity Therapeutics, Inc. Results Intensity Therapeutics, The Ottawa Hospital and Ontario Institute for Cancer Research Report INT230-6 Demonstrates Tumor Necrosis and Immune Activation in Early Stage Breast Cancers intensitytherapeutics.com ↗
Significant Necrosis from a Single Injection of up to 100% of a Tumor was Observed During the Trial
2022-05-26 Takeda Results Takeda and Seagen to Highlight ADCETRIS ® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma takeda.com ↗
These results clearly show that the addition of brentuximab vedotin to chemotherapy improves the long-term outcome of patients and the combination should be considered a standard of care.
2021-11-13 Intensity Therapeutics, Inc. Results Intensity Therapeutics Reports Promising Overall Survival Results Using INT230-6 as a Monotherapy or in Combination with Pembrolizumab or Ipilimumab to Treat Solid Tumors, at The Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting intensitytherapeutics.com ↗
Pharmacokinetic (PK) profile analysis from 18 sarcoma subjects were analyzed for cisplatin, SHAO and vinblastine and showed that greater than 95% of the active drugs remains in the tumor.
2020-11-05 Takeda Results Takeda Oncology Demonstrates Leadership in Hematologic Cancers at 62nd American Society of Hematology (ASH) Annual Meeting takeda.com ↗
Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study.

All press releases naming this drug 8 releases

DateIssuerRelease

Evidence & citations 13 cited values

Every value below carries the sentence it was read from. 208 sources stand behind the page.

FieldValueCited text
Known as VINBLASTINE “Temozolamide 150mg/m2 x4, cisplatin 20mg/m2 x 4, vinblastine 1.2mg/m2 x 4, bevacizumab 7.5-15 mg/kg x 1, interferon 5mg/m2 x5 and aldesleukin 36,18,9, % 9 miu/day over 4 days...” NCT01743157 ↗
194

“OBJECTIVE: To evaluate the efficacy of 4 cycles of vinblastine, Adriamycin (doxorubicin), methotrexate, and prednisone (VAMP) in patients with favorable-risk Hodgkin lymphoma...” PMID 22735430 ↗ Jun 2012

“INT230-6 is a formulation of two well known chemotherapeutic agents, cisplatin (0.5mg/mL) and vinblastine sulfate (0.1mg/mL), combined with 2-hydroxybenzoylaminooctanoate (also...” NCT04781725 ↗

“Chemotherapy is based upon regimes with well known effectiveness in Hodgkin lymphoma. (i.e. ABVD: doxorubicin, bleomycin, vinblastine and dacarbazine and ESHAP: Etoposide,...” NCT03500133 ↗

“Standard neoadjuvant chemotherapy for muscle-invasive bladder cancer, typically consisting of cisplatin-based regimens such as MVAC (methotrexate, vinblastine, doxorubicin, and...” NCT07202819 ↗

“The other drug must contain one of the following: etoposide, vinorelbine, vinblastine, pemetrexed, taxanes (e.g., paclitaxel, docetaxel, albumin paclitaxel, paclitaxel...” NCT06424899 ↗

“MVAC regimen: Methotrexate (30 mg/m2 IV bolus, D1, 15, 22), Vinblastine (3 mg/m2 IV bolus, D2, 15, 22), Doxorubicin (30 mg/m2 IV bolus D2), Cisplatin (70 mg/m2 D2), every 4 weeks” NCT03296306 ↗

“The other half (Group II) will receive a combination of intravenous Adriamycin, Bleomycin, Vinblastine and Dacarbazine every other week for 12 treatments.” NCT00797472 ↗

“ABVD was given every 28 days (doxorubicin 25 mg/m2, bleomycin 10 mg/m2, vinblastine 6 mg/m2, and dacarbazine 375 mg/m2 intravenously on days 1 and 15)” PMID 30658935 ↗ Jan 2019

“DD-MVAC consists of Methotrexate 30 mg/m2 iv day 1, Vinblastine 3 mg/m2 iv day 2, Cisplatin 70 mg/m2 iv day 2 and Doxorubicin 30 mg/m2 iv day 2.” NCT03674424 ↗

“Doxorubicin 25 mg/m2 IV, Bleomycin 10,000 units/m2 IV, Vinblastine 6 mg/m2 IV, Dacarbazine 375 mg/m2 IV on days 1-15 of each 28 day cycle.” NCT02275598 ↗

Show 184 more sources

Known as NSC-49842 “Vinblastine, VBL, NSC-49842; followed by subtotal nodal irradiation as in Arm I.” NCT00002495 ↗
1

“Vinblastine, VBL, NSC-49842” NCT00002462 ↗

Known as VBL “Vinblastine, VBL, NSC-49842; followed by subtotal nodal irradiation as in Arm I.” NCT00002495 ↗
3

“single-drug vinBLAStine (VBL)” NCT07013565 ↗

“Vinblastine, VBL, NSC-49842” NCT00002462 ↗

“VBL” NCT05566795 ↗

Known as Velban “Vinblastine (Velban)” NCT07013565 ↗
2

NCT01404936 ↗

NCT00505635 ↗

Known as Velban(R) (vinblastine) “Velban(R) (vinblastine)” NCT00602667 ↗
Known as Velbe “weekly intra-venous Vinblastine (Velbe©) during 18 courses of 4 weeks each” NCT05180825 ↗
Known as Vinblastina ClinicalTrials.gov intervention name — accepted as the source's own label NCT01067690 ↗
Known as vinblastine sulfate “Treatment with VEPEMB - Vinblastine sulfate, Cyclophosphamide, Procarbazine hydrochloride, Prednisolone, Etoposide, Mitoxantrone hydrochloride, and Bleomycin sulfate” NCT00079105 ↗
15

“Patients receive vinblastine sulfate (5 mg/m2) IV and methotrexate (30 mg/m2) IV weekly for 26 weeks, then every 2 weeks for an additional 26 weeks.” NCT00003019 ↗

“AVD (adriamycin,vinblastine sulfate and dacarbazine)” NCT05772624 ↗

“Drug: vinblastine sulfate” NCT00678327 ↗

“Drug: vinblastine sulfate” NCT00049595 ↗

“Drug: vinblastine sulfate” NCT00028756 ↗

“vinblastine sulfate” NCT00014274 ↗

NCT00822120 ↗

NCT00317408 ↗

NCT00004887 ↗

NCT04383743 ↗

Show 5 more sources

Known as Vinblastine Sulphate “Vinblastine Sulphate chemotherapy via intravenous administration once a week.” NCT00575796 ↗
Known as vinblastine sulphate injection “Drug: vinblastine sulphate injection” NCT00213278 ↗
Action Inhibit “Drugs used in chemotherapy, such as doxorubicin hydrochloride, bleomycin, vinblastine, and dacarbazine, work in different ways to stop the growth of tumor cells” NCT00654732 ↗
Modality Small molecule “the vinca alkaloid vinblastine” NCT00061893 ↗
Route Intravenous “A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer” NCT00001570 ↗